New consolidation announcement
in the CDMO and CRO markets
Thermo Fisher Scientific Inc. is nearing a deal to buy pharmaceutical testing company PPD Inc. for more than $15 billion.
New steps on the road against Covid-19 pandemic
With more than 133.9 million people around the world diagnosed with Covid-19 on April 8, and more than 2.9 million people dead, vaccination campaigns definitely are the main barrier against the pandemic. According to study findings published in the NEJM (New England Journal of Medicine), Moderna's vaccine mRNA-1273 appears to offer protection against Covid-19 for at least six months. Meanwhile, Pfizer and BioNTech's, BNT162b2, is said to be 91.3% effective at preventing the disease.
What is thrombocytopenia,
the rare blood condition possibly linked to the AstraZeneca vaccine?
Follows reports over recent weeks of blood clots in a small number of people around the world who had received the AstraZeneca vaccine. Scientists have termed the condition "vaccine induced prothrombotic immune thrombocytopenia" (VIPIT). But what does this actually mean, how significant is the risk?
Vaccines production accelerates,
so do worldwide death tolls
Will worldwide Covid-19 deaths decrease one day? According to a Reuters tally, they are rising once again, especially in Brazil and India, crossing 3 million on April 6. As it took more than a year for the global coronavirus death toll to reach 2 million, the additional 1 million deaths occurred in about three months, in spite of vaccination efforts across the globe.
CureVac's heavy development partnerships
A day full of news for the two german manufacturers of anti-covid vaccines. On March 30, the two companies involved in developing a messenger RNA vaccine against Covid-19 announced important milestones. BioNTech and partner Pfizer indicated it expected to expand manufacturing capacity to up to 2.5 billion doses by end of 2021, with signed orders for 1.4 billion doses of its vaccine to date for delivery in 2021. Meanwhile CureVac disclosed it was organizing the manufacturing production of its CVnCoV vaccine candidate.
Vaccines against Covid-19 and Liabilities
After Japan, France and the EU,
now the Australian view:
"Liability issues with COVID-19 and
COVID-19 vaccines - who should be
responsible for adverse events?"
Messenger RNA technology:
who is in the race?
Moderna Inc, Pfizer and BioNtech are not the only companies to use messenger RNA (mRNA) in their vaccines projects. Several drug manufacturers are also working hard on this technology to develop treatments and vaccines for various diseases.
Where are the European-manufactured
vaccine doses going?
Last year, much of Europe's leaders watched with dismay as the UK and US governments struggled to deal with the pandemic. The roles quickly changed, with the UK now administering over 40 doses of vaccine per 100 people and the US over 34 doses per 100 people. Within two days, last week, the United States succeeded in vaccinating 6 million people! The European Union administered a first dose to 10.4% of the population only on March 19, 2021 and 4.5% of the population received two doses of the vaccine. ...
API RELOCATION STRATEGIES FOR CDMOS:
short-term emotion or structural reality?
Collectively, we did not see it coming on such a scale. The Covid-19 pandemic has exposed weaknesses in global pharmaceutical supply chains— in particular the dependence on Active Pharmaceutical ingredients (APIs) outsourced to Asia — and governments have responded forcefully with production relocation initiatives. Is this really a structural change or simply a short-term emotion? ...
Covid-19 manufacturing: why agreements between Big Pharma speed up?
With vaccination now well underway in every part of the world, it becomes more and more obvious that vaccine hesitancy is slowing down, whereas the need of millions of jabs is increasing...
Covid-19: four vaccines at a glance
With the FDA's authorization, end of February, for the use of the Johnson & Johnson coronavirus vaccine in adults, the world scientific community now has four different vaccines at its disposal to fight the pandemic.
Mobilization of American drugstores
in the vaccination campaign
Joe Biden has retained Donald Trump's idea: he relies in part on drugstore and supermarket chains to administer millions of covid-19 vaccinations to Americans
What sales for 2020 FDA approved medicines?
With 53 drugs approved by the FDA, 2020 was very dynamic in terms of new approvals in spite of the sanitary crisis and the economic lockdown. But in the end, which products have taken the lead and reached the most sales?
The good performance of CDMOs
on the stock markets.
The values of public CDMO shares continued to outperform in 2020, with growth for the best between 70 and over 90% (Lonza, West Pharma and Catalent).
2020 financial results at a glance
How did major companies manage their businesses in 2020, amid Covid-19 pandemic, economic lockdowns and above all, "ups and downs" in R&D to bring to the market vaccines candidates against the virus?
PHARMAnetwork reviews the Top 5 pharmaceutical companies' 2020 financial results and 2021 forecasts.
Covid-19:
The race for vaccine production capacities
The global market demand for anti-Covid vaccines is much higher than the current production capacities of Western countries. This demand could last for several years depending on several factors such as the duration of the effectiveness of vaccine immunization, the arrival of new variants leading to new vaccination campaigns, etc.